Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $300000.0.

  • Axsome Therapeutics' Gains from Investment Securities fell 9645.13% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 5792.44%. This contributed to the annual value of $8.4 million for FY2024, which is 27.38% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Gains from Investment Securities is $300000.0, which was down 9645.13% from $300000.0 recorded in Q2 2025.
  • Axsome Therapeutics' Gains from Investment Securities' 5-year high stood at $8.9 million during Q2 2024, with a 5-year trough of $38000.0 in Q4 2023.
  • In the last 4 years, Axsome Therapeutics' Gains from Investment Securities had a median value of $2.5 million in 2024 and averaged $3.9 million.
  • Per our database at Business Quant, Axsome Therapeutics' Gains from Investment Securities skyrocketed by 112368.42% in 2024 and then tumbled by 9664.38% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Gains from Investment Securities stood at $739000.0 in 2022, then plummeted by 94.86% to $38000.0 in 2023, then soared by 1123.68% to $465000.0 in 2024, then plummeted by 35.48% to $300000.0 in 2025.
  • Its Gains from Investment Securities stands at $300000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $8.3 million for Q1 2025.